On April 9, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported the appointment of Mani Mohindru, PhD, as President and Chief Executive Officer (CEO), following her time as Interim CEO, and that she will continue as a member of the Board. The Company also appointed Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Operating Officer, effective April 6 and April 27, respectively. Together, these appointments reflect Cardiff’s commitment to building an experienced leadership team to advance onvansertib and deliver on the program’s long-term potential.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am honored to step into the role of Chief Executive Officer at this important time for Cardiff. We have made meaningful progress advancing onvansertib in first-line RAS-mutant metastatic colorectal cancer and remain focused on delivering clinical data to support our registrational program," said Mani Mohindru, PhD, President and Chief Executive Officer. "Building the right team to advance this promising asset is central to our strategy and to ultimately delivering a potential new therapy to patients in need."

Dr. Mohindru continued, "We are excited to welcome Josh and Ajay to our team. Josh is a highly accomplished financial leader with a strong track record of executing complex financings and building trusted relationships across the investment community. Ajay brings deep clinical development and operational expertise, with a proven ability to advance programs from early research through late-stage development. Together, their complementary experience strengthens our ability to execute our strategic priorities."

Josh Muntner

Mr. Muntner brings deep expertise in capital markets strategy, financial operations and supporting clinical-stage organizations through key inflection points. He is a seasoned biopharma finance executive with more than 25 years of experience spanning investment banking and corporate leadership roles, including as CFO of both private and publicly traded biotechnology companies. Previously, Mr. Muntner served as Chief Financial Officer of Imvax, Inc., where he led all finance functions, including raising $86 million in a convertible financing. Prior to that, he served as Chief Financial Officer of Mesoblast Ltd., a Nasdaq- and ASX-listed biotechnology company, where he completed multiple cross-border equity and debt financings totaling approximately $300 million and helped expand the company’s U.S. investor base. Earlier in his career, Mr. Muntner held senior roles in investment banking, completing more than 90 transactions and raising over $9 billion in equity and debt financing for life sciences companies. Mr. Muntner serves as a member of the Board Directors at Devonian Health Group Inc., a biopharmaceutical company developing immunomodulatory treatments for inflammatory diseases.

Mr. Muntner holds an MBA from the UCLA Anderson School of Management and a BFA from Carnegie Mellon University.

Ajay Aggarwal, MD, MBA

Dr. Aggarwal is a board-certified Pulmonary, Critical Care and Sleep Medicine physician with more than 15 years of experience in the pharmaceutical industry, spanning respiratory, immunology and oncology drug development. Most recently, he served as Senior Vice President and Head of Clinical Development at Aclaris Therapeutics, where he led clinical strategy and execution across multiple programs.

Prior to Aclaris, Dr. Aggarwal served as Chief Medical Officer of CereXis, Inc., a company advancing therapies for rare neurology and oncology indications. He has also held clinical leadership roles at Insmed, Inc. and AstraZeneca PLC, where he successfully advanced several compounds from preclinical stages into late-stage clinical development.

Earlier in his career, he held academic leadership roles, including Chief of Medicine at a VA Hospital, and has authored numerous peer-reviewed publications. He is a Fellow of the American College of Chest Physicians.

Dr. Aggarwal received his MBA from the Kellogg School of Management at Northwestern University and his medical degree from the All India Institute of Medical Sciences.

Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

In connection with Mr. Muntner joining Cardiff Oncology, the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 486,650 shares of Cardiff Oncology common stock outside of the Cardiff Oncology 2021 Omnibus Equity Incentive Plan. The stock option was granted as an inducement material to Mr. Muntner becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The option was granted as of April 6, 2026, and has an exercise price of $1.58 per share, the closing price on the grant date. The option vests over four years with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to Mr. Muntner’s continued employment with Cardiff Oncology on such vesting dates.

(Press release, Cardiff Oncology, APR 9, 2026, View Source [SID1234664263])

On April 9, 2026 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science reported that it has entered into a new collaboration agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to advance research in the emerging degrader-antibody conjugate (DAC) modality. Working together, C4T and Roche will combine antibody-drug conjugation (ADC) and targeted protein degradation (TPD) to develop a new way to treat cancers that leverages both the specificity and catalytic efficiency of degraders with the delivery capabilities of ADCs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For the past decade, C4T and Roche have worked together to drive research in targeted protein degradation and to establish this modality as a new way to treat cancer," said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. "Our new collaboration leverages C4T’s ability to design highly catalytic and selective degraders, as well as degrader payloads for DACs, alongside Roche’s extensive experience developing ADCs with specific binding. Together, these capabilities build a powerful new modality that can offer transformative medicines for patients."
"Roche has been a believer in targeted protein degradation and its potential for differentiation early on, when partnering with C4T for the first time in 2016," said Boris Zaïtra, head of corporate business development, Roche. "Our relationship with C4 Therapeutics is built on a decade of trust and shared scientific ambition. We are pleased to enter into our third collaboration, expanding our long-standing partnership to pioneer the emerging modality of degrader-antibody conjugates (DACs)."

Under the joint research plan, C4T and Roche will collaborate on two programs to develop DACs against undisclosed oncology targets exclusive to the collaboration. C4T will use its proprietary TORPEDO platform to design degrader payload candidates. Roche will select and design the antibody as well as conjugate the antibody to the degrader payload. Roche will be responsible for advancing DAC candidates through preclinical and clinical development as well as commercialization.

C4T will receive a $20 million upfront payment for the two programs. Should Roche exercise its option for a third target, C4T will receive an additional payment. Across the collaboration, C4T will receive near-term discovery milestone payments. C4T is eligible to receive over $1 billion in discovery, regulatory and commercial milestone payments. In addition, C4T is entitled to tiered royalties on future sales, subject to reductions under certain circumstances as described in the collaboration agreement.

About Degrader-Antibody Conjugates (DACs)

ADCs over the last 15 years have made important contributions to cancer therapy, but their clinical utility has historically been challenged by a limited therapeutic margin. Degrader-based ADCs, or degrader-antibody conjugates (DACs), represent a potential step-change in this modality. By utilizing degrader payloads that target specific cellular dependencies, DACs offer a superior therapeutic index. These small-molecule degraders are characterized by a catalytic mechanism of action—a feature unique to this approach—rendering them exceptionally well suited for targeted antibody delivery.

(Press release, C4 Therapeutics, APR 9, 2026, View Source [SID1234664262])

On April 9, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that Dr. Amit Kumar, Anixa’s Chairman and CEO, will participate in the upcoming RedChip Biotech Resurgence: Platforms and Pipelines of Today’s Innovators virtual investor conference on April 16, 2026, at 3:30 pm ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will cover several topics, including an overview of the Company and its business model, the Company’s breast cancer vaccine meeting primary endpoints and generating protocol-defined immune responses in 74% of participants in its Phase 1 clinical trial, and the Company’s ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in its ongoing Phase 1 clinical trial.

RedChip’s virtual investor conference brings investors direct access to publicly traded companies advancing the future of healthcare across biopharma, medtech, diagnostics, and digital health. Throughout this full-day virtual event, company executives will present their business models, pipeline strategies, clinical and commercial milestones, and competitive positioning within an evolving healthcare landscape. Each session will include a live Q&A, giving investors the opportunity to engage directly with leadership teams.

Registration to attend this virtual investor conference may be completed at: Event Registration.

(Press release, Anixa Biosciences, APR 9, 2026, View Source [SID1234664261])

On April 8, 2026, IDEAYA Biosciences, Inc. (the "Company") reported to have entered into a clinical collaboration agreement with AstraZeneca plc ("AstraZeneca") to evaluate the efficacy and safety of IDE849, the Company’s investigational, potential first-in-class DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca’s Imfinzi (durvalumab), a programmed death-ligand 1 (PD-L1) inhibitor, in extensive-stage small cell lung cancer ("SCLC"). The Company will sponsor the clinical combination study and AstraZeneca will supply Imfinzi.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company is advancing a multi-site global Phase 1 clinical trial for IDE849 in DLL3 upregulated solid tumor indications, including SCLC, neuroendocrine carcinomas ("NECs"), neuroendocrine tumors ("NETs"), and melanoma. The study will be enrolling patients globally, including in North America, Europe, Australia, South America, and Asia.

DLL3 has been reported to be upregulated in multiple solid tumor types, including in SCLC, NECs, NETs, non-small cell lung cancer, and melanoma, among others. DLL3 has limited extracellular expression in normal tissues, making it a promising potential therapeutic target in these solid tumors, for which there remains significant unmet medical need.

(Press release, Ideaya Biosciences, APR 8, 2026, View Source [SID1234664268])

On April 8, 2026 Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, reported five additional patient cases that management believes further support the potential of its lead candidate in cancer cachexia, advanced cancer supportive care and other serious disease settings characterized by profound physical decline, inflammation, metabolic dysfunction and loss of functional capacity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The five newly highlighted cases follow the Company’s previously disclosed case involving "Johnny," a senior dosimetrist at a premier cancer hospital in the Northeast, whose personal experience management believes provided an initial clinically relevant signal supporting the Company’s strategic interest in cancer cachexia and supportive oncology. Taken together, management believes the growing body of patient accounts may suggest broader potential relevance of the Company’s lead candidate in helping patients maintain or recover appetite, strength, physical condition, mobility, and quality of life in the setting of serious disease.

The newly highlighted cases include:

Advanced Thymic Carcinoma — 52-Year-Old Male Patient

This 52-year-old male patient was receiving care at Memorial Sloan Kettering Cancer Center (MSKCC) for advanced thymic carcinoma with pulmonary embolism, pulmonary hemorrhage, and bilateral lung and pleural metastases. The pleural tumor measured 9.9 × 3.3 cm and was visibly vascularized. His wife recounted that doctors had told them the pain in his left abdomen was so severe it could cause him to faint at any moment — and that if it happened outside the home, he might not make it back. His estimated survival was approximately one month. According to the patient’s account, after taking the Company’s product for approximately 20 days, all pain disappeared, night sweats resolved, hemoptysis stopped, analgesic injections were no longer needed, and his appetite and sleep improved. Visible reduction of the pleural tumor was also reported. According to the patient’s account, his projected survival extended from weeks to more than one year with meaningful improvement in quality of life.

Advanced Small Cell Lung Cancer (SCLC) — 55-Year-Old Female Patient

This 55-year-old female patient was initially evaluated in Flushing, New York, and subsequently referred to Memorial Sloan Kettering Cancer Center (MSKCC) for treatment of metastatic small cell lung cancer. She had visible tumors in her neck, chest, and abdomen, with the largest neck tumor measuring approximately 1 × 1 cm. Her oncologist had told her family to prepare for her passing, saying she had only weeks to live. She had exhausted chemotherapy, radiotherapy, immunotherapy, and investigational therapies. Before taking the Company’s product, she was profoundly cachectic, severely weak, and barely able to eat. According to the patient’s account, within approximately one month, she gained about 17 pounds (~7.7 kg), her voice returned from weak to strong, and she resumed normal eating and physical activity. After approximately two months, she was walking briskly and jogging lightly, and the previously visible neck tumor was no longer detectable. According to the patient’s account, her projected survival extended from weeks to more than three years.

Pancreatic Cancer with Post-Surgical Multi-Organ Complications — 80-Year-Old Male Patient

This 80-year-old male patient developed multi-organ failure following pancreatic cancer resection and was hospitalized for an extended period at NewYork-Presbyterian Hospital in Lower Manhattan. The hospital had notified his family of his critical condition, with expected survival of only days or hours. He was unable to eat, had severe edema in his feet and legs, was severely hypotensive, bedridden, and required nasogastric tube feeding. According to the patient’s account, the morning after taking the Company’s product, he was able to eat small amounts that same evening; within a week, he could eat normally, and his blood pressure and liver and kidney function had returned to normal. Within two weeks, he had regained sufficient strength to be discharged home. After returning home, he went outside daily in a wheelchair for exercise and fresh air, and his mental state continued to improve. According to the patient’s account, his projected survival extended from hours to more than one year with substantial improvement in condition and quality of life.

End-Stage Liver Cirrhosis with Massive Ascites and Hepatorenal Syndrome — 82-Year-Old Male Patient, Chris

Chris, an 82-year-old male patient who had been under the long-term care of physicians at MSKCC, developed end-stage liver cirrhosis with massive ascites, causing his abdomen to swell to the size of a full-term pregnancy. He was extremely weak, unable to get out of bed independently, unable to walk, barely able to eat, and had been unable to urinate spontaneously for over a year, relying on daily drainage of ascitic fluid. After being told no further treatment options were available, he entered hospice care with an estimated life expectancy of one to two months. According to the patient’s account, on the fourth day after taking the Company’s product, he urinated in large quantities, and his appetite returned. By day eleven, the drainage tube had stopped producing fluid. After one month, he was using a walker and riding a stationary bicycle to exercise his legs, and was eating regularly. After two months, he was walking freely and cooking in the kitchen — and the abdomen had completely returned to normal. After three months, he had the energy to walk normally. According to the patient’s account, he subsequently survived for more than one year with improved mobility and quality of life.

End-Stage Renal Disease (ESRD) with Pleural Effusion, Hydronephrosis and Neuropathic Pain — 76-Year-Old Male Patient

This 76-year-old male patient with end-stage renal disease had been receiving thrice-weekly hemodialysis at North Flushing Dialysis Center. He was physically weak and could only walk slowly with a cane, suffering from severe bilateral leg pain, severe pleural effusion, hydronephrosis, and complete loss of spontaneous urination. According to the patient’s account, spontaneous urination returned within approximately one week of taking the Company’s product. Follow-up imaging subsequently confirmed complete resolution of both pleural effusion and hydronephrosis, bilateral leg pain fully resolved, and his physical strength recovered significantly. His mental state and overall condition continued to improve, and he was able to walk more than 10,000 steps per day independently, without any assistive device. Management believes this case is noteworthy because it reflects severe systemic decline involving inflammation, metabolic disruption, fluid accumulation, and loss of physical function — features that overlap substantially with broader wasting syndromes.

Management noted that across these five cases, spanning very different disease backgrounds, a consistent set of themes emerged: severe weakness, loss of appetite, impaired mobility, profound physical deterioration, metabolic instability, and loss of independent function. In several cases, according to patient accounts, improvements in overall physical condition helped patients regain the ability to eat, walk, sleep, and live more normally. Management believes these observations are particularly relevant in the context of cancer cachexia and supportive oncology, where maintaining physical condition and functional status can be highly meaningful for both quality of life and the ability to continue receiving care.

"What stands out to us is not simply the severity of these cases, but that across very different disease settings, we are repeatedly hearing from patients about the return of appetite, the rebuilding of strength, the ability to walk again, and the return to ordinary daily life," said Jun Liu, Chief Executive Officer of Curanex. "We believe this growing body of patient experience may support the possibility that our lead candidate has broader relevance in one of the most difficult areas of medicine: helping seriously ill patients maintain or rebuild the physical resilience they need to endure disease. If future research supports these observations, we believe the implications for cancer cachexia, supportive oncology, and other serious diseases involving systemic decline could be medically important and commercially significant."

As previously announced, Curanex has expanded its strategic development focus to include cancer cachexia, which management believes represents one of the largest unmet needs in supportive oncology. The Company believes this market opportunity is supported by the seriousness of the condition, the absence of approved therapies in the United States specifically for cancer cachexia, and the potential value of any candidate capable of helping patients maintain body weight, appetite, strength, mobility, or the ability to continue receiving care. The Company also believes these patient observations are consistent with its broader strategic interest in diseases involving inflammation, metabolic disruption, and physical decline.

Curanex cautions that the above reports reflect only individual patient accounts, are observational in nature, and do not establish safety or efficacy or predict similar outcomes in other patients. The Company believes, however, that the consistency of certain observations across multiple severe cases may help inform future development priorities in cancer cachexia, advanced cancer supportive care, and other serious disease settings.

(Press release, Curanex Pharmaceuticals, APR 8, 2026, View Source [SID1234664260])